Aegis Capital Upgrades Pernix Therapeutics (PTX) to Buy; Notes 'Transformative' Treximet Purchase
Tweet Send to a Friend
Aegis Capital raises Pernix Therapeutics Holdings (Nasdaq: PTX) from Hold to Buy with a price target of $9.Analyst Ram Selvaraju ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
